Solubility: Soluble in DMSO (up to 2 mg/ml under heating conditions)
pKa: 8.66±0.10 (predicted value)
III. Biological Activity and Pharmacological Effects
Palbociclib is an orally available pyrido[2,3-d]pyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antitumor activity. It is a highly specific inhibitor of CDK4 and CDK6, with IC50 values of 0.011 μmol/L and 0.016 μmol/L, respectively, and inactive against other 36 protein kinases. By inhibiting the activity of CDK4/6 enzymes, Palbociclib can target tumor cells and restore cell cycle control, thereby blocking tumor cell proliferation.